Loews Aktie News

NEW YORK, 4. Aug. 2026 /PRNewswire/ -- Loews Corporation (NYSE: L) gab heute die Festlegung der vierteljährlichen Dividende des Unternehmens in Höhe von $0,0625 je Stammaktie bekannt, zahlbar am 1. September 2026 an Aktionäre, die zum Handelsschluss am 19. August 2026 als Bestandshalter eingetragen sind. Loews Corporation ist ein diversifiziertes Unternehmen mit Geschäften in den Bereichen Vers...

NEW YORK, 3. Aug. 2026 /PRNewswire/ -- Loews Corporation (NYSE: L) veröffentlichte heute seine Finanzergebnisse für das zweite Quartal 2026. Höhepunkte des zweiten Quartals 2026: Loews Corporation meldete im zweiten Quartal 2026 einen Nettogewinn von 444 Mio. USD bzw. 2,16 USD je Aktie, gegenüber 391 Mio. USD bzw. 1,87 USD je Aktie im zweiten Quartal 2025.

As EQB prepares to close its Acquisition of PC Financial on July 1, 2026, the company announces a strengthened leadership team drawing on talent from both organizations, positioning EQB for a differentiated phase of growth Key appointments include: Ian Hanning from PC Financial to SVP, Credit Cards and Loyalty Mark Snyder from PC Financial to SVP, Credit Risk and Data Analytics Michaela Garfiel...

Transformative partnership between Tsuut'ina Nation, Taza Development Corp. and Real Canadian Superstore advances as opening preparations get underway Transformative partnership between Tsuut'ina Nation, Taza Development Corp. and Real Canadian Superstore advances as opening preparations get underway

TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- In the latest edition of its Food Inflation Report, Loblaw is pleased to provide context around what's impacting food prices – now and into the future. This report follows Statistics Canada's release of data for the month of April.

TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Ahead of Menstrual Health Day on May 28, Shoppers Foundation for Women's Health™ is proud to announce $300,000 in funding commitments over two years to support organizations advancing menstrual equity in Canada.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) as a monotherapy for the treatment of adult patients with unresectable locally advanced o...

BRAMPTON, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Being an Insider is all about the thrill of discovery, that can't-wait-to-see-what's-next energy. Here at President's Choice, we're always pushing new taste possibilities.